The inhibition of atRA- and COUP-TFII- regulated RARB2 expression by AS1411 may also be independent of its effect on nucleolin and may indicate a potential adverse ‘side effect’ of AS1411 that may be a concern if this drug is used for breast cancer therapy. The gene discussed is NUCLEOLIN; the disease is breast cancer.